Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

The study will include up to 3 cohorts, with 12 subjects in each, for a total of up to 36 randomised subjects. The study comprises a screening period of up to 49 days, an 8-week double-blind treatment period, and a 13-week follow-up period. Each subject will receive three 60 minute iv infusions of MEDI1341 or placebo during the 8-week treatment period, with 4 weeks between infusions. The overall study duration (enrolment, treatment, and follow-up periods) will be up to 28 weeks per subject. A Dose Escalation Committee will review data from each cohort to allow progression to the next higher dose cohort in the study.